Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae

Microbial Pathogenesis

Volumn 44, Issue 3, 2008, Pages 204-214

  Ochs, Martina M ^a   Bartlett, William ^b   Briles, David E ^c,d   Hicks, Bryony ^a   Jurkuvenas, Audra ^a   Lau, Peggy ^a   Ren, Bing ^c   Millar, Amanda ^a  

^a Sanofi Pasteur   (Canada)

^b SANOFI PASTEUR   (France)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Antibody; C3; Complement; Pneumococcal surface protein A; PspA; Streptococcus pneumoniae

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; COMPLEMENT COMPONENT C3; MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; COMPLEMENT DEPOSITION; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; STREPTOCOCCUS PNEUMONIA;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT C3; HUMANS; PNEUMOCOCCAL VACCINES; RABBITS; STREPTOCOCCUS PNEUMONIAE;

ORYCTOLAGUS CUNICULUS; STREPTOCOCCUS PNEUMONIAE;

EID: 38549123474     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2007.09.007     Document Type: Article

References (57)

1. Whitney C.G., Schaffner W., and Butler J.C. Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis 33 5 (2001) 662-675
2. Obaro S.K. The new pneumococcal vaccine. Clin Microbiol Infect 8 10 (2002) 623-633
3. Dowell S.F. A new imperative of global pneumonia control: a commentary. Pediatr Infect Dis J 26 (2007) 441-442
4. Whitney C.G., and Pickering L.K. The potential of pneumococcal conjugate vaccines for children. Pediatr Infect Dis J 21 10 (2002) 961-970
5. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 9 (2002) 810-815
6. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 33 10 (1995) 2759-2762
7. Castaneda E., Leal A.L., Castillo O., De La Hoz F., Vela M.C., Arango M., et al. Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children. Pneumococcal Study Group in Colombia. Microb Drug Resist 3 2 (1997) 147-152
8. Mollerach M., Regueira M., Bonofiglio L., Callejo R., Pace J., Di Fabio J.L., et al. Invasive Streptococcus pneumoniae isolates from Argentinian children: serotypes, families of pneumococcal surface protein A (PspA) and genetic diversity. Epidemiol Infect 132 2 (2004) 177-184
9. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 (2007) 1784-1792
10. Feikin D.R., and Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 35 5 (2002) 547-555
11. Crain M.J., Waltman II W.D., Turner J.S., Yother J., Talkington D.F., McDaniel L.S., et al. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun 58 10 (1990) 3293-3299
12. Vela Coral M.C., Fonseca N., Castaneda E., Di Fabio J.L., Hollingshead S.K., and Briles D.E. Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis 7 5 (2001) 832-836
13. Hollingshead S.K., Baril L., Ferro S., King J., Coan P., and Briles D.E. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol 55 Part 2 (2006) 215-221
14. Hollingshead S.K., Becker R., and Briles D.E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68 10 (2000) 5889-5900
15. Yother J., and Briles D.E. Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol 174 2 (1992) 601-609
16. McDaniel L.S., McDaniel D.O., Hollingshead S.K., and Briles D.E. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun 66 10 (1998) 4748-4754
17. Nabors G.S., Braun P.A., Herrmann D.J., Heise M.L., Pyle D.J., Gravenstein S., et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies. Vaccine 18 (2000) 1743-1754
18. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with rPspA elicits antibodies, which passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182 (2000) 1694-1701
19. Hosea S.W., Brown E.J., and Frank M.M. The critical role of complement in experimental pneumococcal sepsis. J Infect Dis 142 6 (1980) 903-909
20. Brown J.S., Hussell T., Gilliland S.M., Holden D.W., Paton J.C., Ehrenstein M.R., et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci USA 99 26 (2002) 16969-16974
21. Ren B., Szalai A.J., Hollingshead S.K., and Briles D.E. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72 1 (2004) 114-122
22. Walport M.J. Complement. First of two parts. N Engl J Med 344 14 (2001) 1058-1066
23. Tu A.H., Fulgham R.L., McCrory M.A., Briles D.E., and Szalai A.J. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 67 9 (1999) 4720-4724
24. Neeleman C., Geelen S.P., Aerts P.C., Daha M.R., Mollnes T.E., Roord J.J., et al. Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun 67 9 (1999) 4517-4524
25. Ren B., Szalai A.J., Thomas O., Hollingshead S.K., and Briles D.E. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 71 1 (2003) 75-85
26. Tu A.-H.T., Fulgham R.L., McCory M.A., Briles D.E., and Szalai A.J. Pneumococcal surface protein A (PspA) inhibits complement activation by Streptococcus pneumoniae. Infect Immun 67 (1999) 4720-4724
27. Tart R.C., McDaniel L.S., Ralph B.A., and Briles D.E. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 173 2 (1996) 380-386
28. Briles D.E., King J.D., Gray M.A., McDaniel L.S., Swiatlo E., and Benton K.A. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in 26 mice. Vaccine 14 9 (1996) 858-867
29. Briles D.E., Hollingshead S.K., Nabors G.S., Paton J.C., and Brooks-Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19 Suppl. 1 (20008) S87-S95
30. Roche H., Hakansson A., Hollingshead S.K., and Briles D.E. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun 71 3 (2003) 1033-1041
31. Roche H., Ren B., McDaniel L.S., Hakansson A., and Briles D.E. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun 71 8 (2003) 4498-4505
32. McDaniel L.S., Ralph B.A., McDaniel D.O., and Briles D.E. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 17 5 (1994) 323-337
33. Nabors G.S., Braun P.A., Herrmann D.J., Heise M.L., Pyle D.J., Gravenstein S., et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18 17 (2000) 1743-1754
34. Ren B., Szalai A.J., Hollingshead S.K., and Briles D.E. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72 (2004) 114-122
35. McDaniel L.S., Loechel F., Benedict C., Greenway T., Briles D.E., Conry R.M., et al. Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae. Gene 188 (1997) 279-284
36. Lancefield R.C. Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med 106 (1957) 525-544
37. Briles D.E., Forman C., Horowitz J.C., Volanakis J.E., Benjamin Jr. W.H., McDaniel L.S., et al. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 57 (1989) 1457-1464
38. Hollingshead S.K., Becker R.S., and Briles D.E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68 (2000) 5889-5900
39. Brown E.J., Hosea S.W., and Frank M.M. The role of complement in the localization of pneumococci in the splanchnic reticuloendothelial system during experimental bacteremia. J Immunol 126 6 (1981) 2230-2235
40. Figueroa J.E., and Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4 3 (1991) 359-395
41. Szalai A.J., Briles D.E., and Volanakis J.E. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun 64 11 (1996) 4850-4853
42. Yuste J., Ali S., Sriskandan S., Hyams C., Botto M., and Brown J.S. Roles of the alternative complement pathway and C1q during innate immunity to Streptococcus pyogenes. J Immunol 176 10 (2006) 6112-6120
43. Nahm M.H., Apicella M.A., and Briles D.E. Immunity to extracellular bacteria. In: Paul W.E. (Ed). Fundamental immunology (1999), Lippincott-Raven, Philadelphia 1373-1386
44. Yu X., Gray B., Chang S., Ward J.I., Edwards K.M., and Nahm M.H. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 180 5 (1999) 1569-1576
45. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4 4 (1997) 415-422
46. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182 6 (2000) 1694-1701
47. Roche H., Ren B., McDaniel L.S., Hakansson A., and Briles D.E. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun 71 (2003) 4498-4505
48. Lifshitz S., Dagan R., Shani-Sekler M., Grossman N., Fleminger G., Friger M., et al. Age-dependent preference in human antibody responses to Streptococcus pneumoniae polypeptide antigens. Clin Exp Immunol 127 2 (2002) 344-353
49. Briles D.E., Scott G., Gray B., Crain M.J., Blaese M., Nahm M., et al. Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides. J Infect Dis 155 6 (1987) 1307-1314
50. Rapola S., Jantti V., Haikala R., Syrjanen R., Carlone G.M., Sampson J.S., et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 182 4 (2000) 1146-1152
51. Baril L., Briles D.E., Crozier P., King J., Punar M., Hollingshead S.K., et al. Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease. Vaccine 23 6 (2004) 789-793
52. McDaniel L.S., Yother J., Vijayakumar M., McGarry L., Guild W.R., and Briles D.E. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 165 2 (1987) 381-394
53. Ren B., Szalai A.J., Thomas O., Hollingshead S.K., and Briles D.E. Both family 1 and family 2 PspAs can inhibit complement deposition and confer virulence to a capsular 3 serotype Streptococcus pneumoniae. Infect Immun 71 (2003) 75-85
54. Briles D.E., Nahm M., Schroer K., Davie J., Baker P., Kearney J., et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med 153 3 (1981) 694-705
55. Yother J., Handsome G.L., and Briles D.E. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol 174 (1992) 610-618
56. McDaniel L.S., Scott G., Kearney J.F., and Briles D.E. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med 160 2 (1984) 386-397
57. Briles D.E., Crain M.J., Gray B.M., Forman C., and Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 60 1 (1992) 111-116